Brief: Celon Pharma Files Marketing Authorization Applications In EU For Semaglutide Drug Injection Solution
16/10/2026 06:27
BRIEF-Celon Pharma Files Marketing Authorization Applications In EU For Semaglutide Drug Injection Solution Oct 16 (Reuters) - Celon Pharma SA CLNP.WA:
FILES MARKETING AUTHORIZATION APPLICATIONS IN EU FOR SEMAGLUTIDE DRUG INJECTION SOLUTION
GERMANY AND AUSTRIA TO SERVE AS REFERENCE STATES UNDER APPLICATION PROCEDURE
Source text: ID:nEM9cQQT2a
Further company coverage: CLNP.WA
(Reporting by Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com;))
Recent news on Celon Pharma SA
See all newsBrief: Celon Pharma Projects Recommended For About 29.9 Mln Zlotys Funding By Poland's Medical Research Agency
Brief: Celon Pharma Files Marketing Authorization Applications In EU For Semaglutide Drug Injection Solution
Brief: Celon Pharma Q2 Net Loss At 30.6 Million Zlotys
Brief: Celon Pharma Gets Positive Opinion Confirming Reduzek Compliance With Safety Requirements
Celon Pharma's generic semaglutide drug matches Ozempic in early study, shares jump